插入 IS 会创建一个混合启动子，导致对新型 β-内酰胺/β-内酰胺酶抑制剂组合和头孢地尔的耐药性。
Insertion of IS in IS Creates a Hybrid Promoter for Resulting in Resistance to Novel β-lactam/β-lactamase Inhibitor Combinations and Cefiderocol.
机构信息
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
出版信息
Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0013523. doi: 10.1128/aac.00135-23. Epub 2023 May 22.
Abstract
Eleven -positive Pseudomonas aeruginosa clinical isolates showed variable susceptibility to ceftazidime-avibactam (CZA). The genetic contexts of were identical (IS--) except for the ST697 isolate HS204 (IS-IS--). The insertion of IS in IS upstream of created a hybrid promoter, which elevated the transcription level and resulted in increased resistance to CZA, ceftolozane-tazobactam, cefepime-zidebactam, and cefiderocol. Diversity in the promoter activity of partially explains the variable susceptibility to CZA in PER-producing isolates.
摘要
11 株耐头孢他啶-阿维巴坦的绿脓假单胞菌临床分离株对头孢他啶-阿维巴坦（CZA）的敏感性存在差异。除 ST697 分离株 HS204（IS-IS--）外，其余 10 株的 基因结构相同（IS--）。插入到 上游的 IS 创造了一个杂合启动子，提高了 转录水平，导致对 CZA、头孢洛扎他唑巴坦、头孢吡肟-齐多夫坦和头孢地尔西丁的耐药性增加。 在 PER 产生菌中， 启动子活性的多样性部分解释了对 CZA 敏感性的差异。
相似文献
1
Insertion of IS in IS Creates a Hybrid Promoter for Resulting in Resistance to Novel β-lactam/β-lactamase Inhibitor Combinations and Cefiderocol.
Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0013523. doi: 10.1128/aac.00135-23. Epub 2023 May 22.
2
Comparison of Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa.
Microbiol Spectr. 2023 Jun 15;11(3):e0093223. doi: 10.1128/spectrum.00932-23. Epub 2023 May 18.
3
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother. 2022 Sep 30;77(10):2809-2815. doi: 10.1093/jac/dkac241.
4
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
J Antimicrob Chemother. 2019 Jul 1;74(7):1934-1939. doi: 10.1093/jac/dkz149.
5
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Int J Antimicrob Agents. 2023 Apr;61(4):106744. doi: 10.1016/j.ijantimicag.2023.106744. Epub 2023 Feb 3.
6
Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
Microbiol Spectr. 2022 Oct 26;10(5):e0169722. doi: 10.1128/spectrum.01697-22. Epub 2022 Oct 3.
7
Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of in China from 2010 to 2022.
Emerg Microbes Infect. 2024 Dec;13(1):2324068. doi: 10.1080/22221751.2024.2324068. Epub 2024 Mar 11.
8
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
J Antimicrob Chemother. 2023 May 3;78(5):1195-1200. doi: 10.1093/jac/dkad062.
9
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
Clin Infect Dis. 2019 May 17;68(11):1823-1830. doi: 10.1093/cid/ciy801.
10
Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0003922. doi: 10.1128/aac.00039-22. Epub 2022 Mar 22.
引用本文的文献
1
In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.
Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1041-1068. doi: 10.1007/s10096-025-05080-1. Epub 2025 Mar 10.
2
Characterization and Implications of IncP-2A Plasmid pMAS152 Harboring Multidrug Resistance Genes in Extensively Drug-Resistant .
Microorganisms. 2024 Mar 12;12(3):562. doi: 10.3390/microorganisms12030562.
3
Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of in China from 2010 to 2022.
Emerg Microbes Infect. 2024 Dec;13(1):2324068. doi: 10.1080/22221751.2024.2324068. Epub 2024 Mar 11.
本文引用的文献
1
An XDR Pseudomonas aeruginosa ST463 Strain with an IncP-2 Plasmid Containing a Novel Transposon Tn Encoding and and a Second Plasmid with Two Copies of .
Microbiol Spectr. 2023 Feb 14;11(1):e0446222. doi: 10.1128/spectrum.04462-22. Epub 2023 Jan 18.
2
Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0003922. doi: 10.1128/aac.00039-22. Epub 2022 Mar 22.
3
Alcaligenes faecalis metallo-β-lactamase in extensively drug-resistant Pseudomonas aeruginosa isolates.
Clin Microbiol Infect. 2022 Jun;28(6):880.e1-880.e8. doi: 10.1016/j.cmi.2021.11.012. Epub 2021 Nov 24.
4
Characterization of the novel plasmid-encoded MBL gene blaAFM-1, integrated into a blaIMP-45-bearing transposon Tn6485e in a carbapenem-resistant Pseudomonas aeruginosa clinical isolate.
J Antimicrob Chemother. 2021 Dec 24;77(1):83-88. doi: 10.1093/jac/dkab342.
5
An IncP-2 plasmid sublineage associated with dissemination of among carbapenem-resistant .
Emerg Microbes Infect. 2021 Dec;10(1):442-449. doi: 10.1080/22221751.2021.1894903.
6
Plasmids of novel incompatibility group IncpRBL16 from Pseudomonas species.
J Antimicrob Chemother. 2020 Aug 1;75(8):2093-2100. doi: 10.1093/jac/dkaa143.
7
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
J Antimicrob Chemother. 2019 Jul 1;74(7):1934-1939. doi: 10.1093/jac/dkz149.
8
panISa: ab initio detection of insertion sequences in bacterial genomes from short read sequence data.
Bioinformatics. 2018 Nov 15;34(22):3795-3800. doi: 10.1093/bioinformatics/bty479.
9
Transposition of Tn Encoding the PER-1 Extended-Spectrum β-Lactamase.
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02453-17. Print 2018 Mar.
10
Complete sequence of pBM413, a novel multidrug resistance megaplasmid carrying qnrVC6 and bla from pseudomonas aeruginosa.
Int J Antimicrob Agents. 2018 Jan;51(1):145-150. doi: 10.1016/j.ijantimicag.2017.09.008. Epub 2017 Sep 18.
Zotero 插件